Article info
PDFCystic fibrosis
Original article
Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation
- Correspondence to Dr JP Clancy, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH 45229, USA; john.clancy{at}cchmc.org
Citation
Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation
Publication history
- Received April 29, 2011
- Accepted July 1, 2011
- First published August 8, 2011.
Online issue publication
September 01, 2022
Article Versions
- Previous version (29 April 2016).
- Previous version (9 January 2022).
- You are viewing the most recent version of this article.
Web Only Data thoraxjnl-2011-200393
Files in this Data Supplement:
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© 2011, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.